Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 161

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 161
---
 and dental care; (ii) long
term disability protection plans; (iii) life insurance; and (iv) a 401(k) savings plan.

E. Share
Ownership

For information regarding the share ownership of our directors
and executive officers, please refer to the table in “ Item 7. Major Shareholders and Related Party Transactions - A. Major
Shareholders.” For information regarding our equity incentive plans, see “ Item 6. B. Director, Senior Management and Employees - Compensation - Equity
Incentive Plans. ”

  F. Disclosure                                                         

None.

  ITEM 7.      MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS  
 ──────────────────────────────────────────────────────────────────

A. Major
Shareholders

The following table sets forth information with respect to the
beneficial ownership of our shares as of March 17, 2025 (unless otherwise indicated) by: (i) each of our directors and executive officers,
individually; and (ii) all of our executive officers and directors, as a group. There is no person or entity known by us to own beneficially
more than 5% of our outstanding shares.

The beneficial ownership of ordinary shares is determined in accordance
with the rules of the SEC, and generally includes any ordinary shares over which a person exercises sole or shared voting or investment
power, or the right to receive the economic benefit of ownership. For purposes of the table below, we deem shares subject to warrants
and options that are currently exercisable or exercisable within 60 days of March 17, 2025, and RSUs that are currently vested or
will become vested within 60 days of March 17, 2025, to be outstanding and to be beneficially owned by the person holding the warrants
or options for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose
of computing the percentage ownership of any other person.

The percentage of shares beneficially owned by any shareholder
has been calculated based on 6,672,173 ordinary shares outstanding as of March 17, 2025. Unless otherwise indicated below, to our
knowledge, all persons named in the table have sole voting and investment power with respect to their shares, except to the extent that
authority is shared by spouses under community property laws.

Unless otherwise noted below, each shareholder’s address
is c/o Evogene Ltd., 13 Gad Feinstein Street, Park Re